Skip to content

Research for the Precision Medicine in the Treatment of Inflammatory Bowel Disease

Convergence Research Platform for the Precision Medicine in the Treatment of Inflammatory Bowel Disease

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07166588
Acronym
PREDICT
Enrollment
2000
Registered
2025-09-10
Start date
2021-01-20
Completion date
2028-12-31
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease (CD), IBD (Inflammatory Bowel Disease), Ulcerative Colitis (UC)

Keywords

Ulcerative Colitis, Inflammatory Bowel Disease, Crohn Disease

Brief summary

This study aims to establish an integrated cohort of patients with inflammatory bowel disease (IBD) from Seoul National University Hospital, Seoul National University Boramae Medical Center, and Seoul National University Bundang Hospital. Through this cohort, we seek to develop a prognostic prediction model for IBD patients and a predictive model for therapeutic responses to biologic agents and small molecule therapies.

Interventions

None listed

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
10 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged 10 years or older who have been newly diagnosed with inflammatory bowel disease or are under follow-up monitoring.

Exclusion criteria

* Patients diagnosed with cancer or with a history of cancer treatment. * Participation may be restricted at the discretion of the medical team. * Infants and young children under the age of 10.

Design outcomes

Primary

MeasureTime frameDescription
Prediction model in the patients with inflammatory bowel disease for treatment responseFrom enrollment to the end of treatment at 12 weeksDevelopment of a prognostic prediction model for patients with inflammatory bowel disease and a predictive model for therapeutic response to biologic agents and small molecule therapies

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026